Whether GLP1-RA improve or worsen eating disorders is an important clinical question
Salonen T, Jokinen E, Satokari R, Lahtinen P
Medical experts have warned of significant health risks to members of the public after it emerged that an experimental weight loss medication, which has no regulatory approval worldwide, is being sold on the Irish black market
At the level of the microbiotaimmuneneural interface, DA and NE not only act as neuromodulators but also influence bacterial growth and virulence, creating bidirectional feedback between catecholaminergic tone and microbial composition [209,210]
We believe that this difference may be related to the ability of caffeine to inhibit appetite, as it has neuroexcitatory effects (Figures 3A,B)
How do DPP-4 enzyme inhibitor drugs differ from GLP-1 drugs like Ozempic